For a patient with bipolar I disorder, the choice between lithium and valproate can shape the course of their illness. Lithium, the gold-standard mood stabilizer, demands regular blood tests to keep serum levels within a narrow therapeutic window. Valproate, a cheaper alternative, requires less monitoring and is often the default in public mental health clinics across low- and middle-income countries. But patients with means are increasingly bypassing the public system, purchasing lithium from private pharmacies—sometimes without a prescription or follow-up. This creates a two-tier reality where the best treatment is available only to those who can pay out-of-pocket.

Why a Bipolar Patient Might Pay for Lithium While Public Clinics Default to Valproate

The clinical guidelines are clear: lithium is the first-line maintenance therapy for bipolar disorder, supported by decades of evidence. Yet in practice, many public clinics prescribe valproate instead. The reason is not pharmacological superiority but logistical convenience. Lithium requires regular monitoring of serum levels, renal function, and thyroid function—tests that strain underfunded laboratories. Valproate, by contrast, has a wider safety margin and needs only occasional liver function checks.

For a patient attending a public clinic in Mumbai, the difference is stark. Valproate is dispensed for free. Lithium, if prescribed, would require the patient to pay for blood tests at a private lab, then return to the clinic for dose adjustments—a process that can take months to stabilize. Many clinicians default to valproate simply because the system cannot support lithium. Those who insist on lithium often end up purchasing it from a private pharmacy, where a month's supply costs roughly ₹600–900 ($7–11), a significant sum for a daily wage earner.

The tension between guideline and reality is not unique to India. In South Africa, national mental health programs cap drug spending, and lithium's per-day cost of about $0.50 compares unfavorably to valproate's $0.15. Procurement contracts favor bulk purchases of valproate, and clinicians report feeling pressured to prescribe it even when they believe lithium would be more effective. No formal policy mandates this, but informal rationing occurs at every level.

This practice has consequences. A 2023 survey of 212 patients at a public clinic in Mumbai, conducted by researchers at King Edward Memorial Hospital, found that only 12% were on lithium, while 68% were on valproate. Among those who could afford private care, the proportion on lithium was nearly 40%. The divide mirrors broader patterns in global mental health: those with resources access the gold standard; those without make do with what the system can provide.

The Two-Tier Reality of Mood Stabilizer Access in Urban India

The Mumbai survey offers a snapshot of how access plays out in practice. Patients who purchased lithium from private pharmacies paid roughly ₹600–900 per month—a significant but manageable cost for a middle-class family, but prohibitive for a laborer earning ₹10,000 a month. Those who received valproate from the public clinic paid nothing. The trade-off was not just financial: lithium requires a disciplined monitoring schedule that many patients could not maintain.

Dr. Anjali Sharma, a psychiatrist at the clinic, told researchers that she prescribes lithium only when a patient can demonstrate reliable access to a private lab. She estimates that fewer than one in five of her patients meet that threshold. For the rest, valproate is the pragmatic choice. “I know lithium is better,” she said, “but I also know that without monitoring, it can be dangerous. Valproate is safer in this context.”

The private pharmacies that fill the gap operate with minimal oversight. In many Indian states, lithium is classified as a schedule H drug, requiring a prescription, but enforcement is lax. Patients can often buy it over the counter, especially if they are regular customers. Pharmacists rarely check for drug interactions or advise on monitoring. A case report from Lagos described a woman with bipolar disorder who presented to an emergency department with a serum lithium level of 2.1 mEq/L—nearly double the upper limit of the therapeutic range. She had been buying lithium from a private pharmacy and had not seen a doctor in 18 months. After stabilization, she was switched to valproate, but the episode illustrated the dangers of unsupervised access.

Lithium's Narrow Therapeutic Window Demands Infrastructure Public Systems Struggle to Provide

Lithium's therapeutic window—typically 0.6 to 1.2 mEq/L—is narrow. Below that range, it offers little protection against mood episodes; above it, toxicity sets in. Maintaining that window requires regular blood draws, reliable laboratory equipment, and clinicians who can interpret results and adjust doses. In many public facilities, even basic phlebotomy services are stretched. In rural Kenya, a study found that fewer than half of primary health centers had a functional centrifuge for serum separation. In Brazil's public system, patients often wait weeks for lab results.

The World Health Organization includes both lithium and valproate on its Model List of Essential Medicines, acknowledging that both have roles. But the list does not account for the infrastructure needed to use lithium safely. Valproate's wider safety margin—therapeutic levels range from 50 to 100 μg/mL, and toxicity is less common at standard doses—makes it more forgiving in settings where monitoring is irregular.

Some clinicians argue that the gap is overstated. Dr. Paulo Costa, a psychiatrist at the University of São Paulo, notes that valproate also requires monitoring, particularly for liver function and platelet count, and that these tests are not always available either. “The difference is one of degree, not kind,” he says. But the threshold for harm is different: a missed lithium level can lead to acute toxicity within days; a missed valproate level is less immediately dangerous.

The infrastructure deficit is not just about equipment. It is about trained personnel. Lithium management requires clinicians who understand its pharmacokinetics and can adjust doses based on renal function, drug interactions, and hydration status. In many public clinics, such expertise is concentrated in a few specialists, while general practitioners manage the bulk of patients. Valproate's simpler dosing reduces the cognitive load, but it may come at the cost of suboptimal outcomes.

When Guidelines Clash with Budget Caps, Valproate Wins by Default

National mental health programs in countries like South Africa, Nigeria, and Indonesia operate under strict budget constraints. Drug procurement is centralized, and tenders are awarded to the lowest bidder. Valproate is typically cheaper than lithium on a per-dose basis, and its longer shelf life and simpler storage requirements make it more attractive for bulk purchasing. As a result, public formularies often list valproate as the preferred mood stabilizer, with lithium reserved for second-line use.

This is not a formal policy in most places, but it operates as a de facto guideline. Clinicians in South Africa report that their pharmacy will stock valproate but not lithium unless a specific request is made, and even then, the lithium may arrive weeks later. In Nigeria, the Federal Neuropsychiatric Hospital in Lagos dispenses valproate to outpatients at no cost, but lithium must be purchased from the hospital pharmacy at market price. A month's supply costs about ₦4,000 ($5), which is affordable for some but not for the many patients who live on less than $2 a day.

The cost difference is not trivial. A 2022 analysis in the Journal of Global Health estimated that switching all eligible patients from valproate to lithium in India would increase the annual drug budget for bipolar disorder by roughly 40%, assuming current prices. That figure does not account for the additional costs of monitoring, which could double the total. For cash-strapped ministries of health, the trade-off is clear: valproate offers acceptable efficacy at a fraction of the cost.

But the calculus changes when long-term outcomes are considered. Lithium has been shown to reduce suicide risk in bipolar patients by roughly 40%, an effect that valproate does not replicate. A 2021 meta-analysis in The Lancet Psychiatry found that lithium was superior to valproate in preventing both manic and depressive relapses. The question is whether the health system can afford to ignore these benefits, or whether it is willing to accept worse outcomes for the majority in order to treat a larger number of patients within a fixed budget.

Private Pharmacies Fill the Gap, but at a Cost to Equity

Private pharmacies have become the de facto access point for lithium in many low- and middle-income countries. In Lagos, a survey of 50 pharmacies found that 42 stocked lithium, and 35 would sell it without a prescription. In Mumbai, the proportion was similar. The price is roughly double what the public system pays, but for patients who can afford it, the convenience is worth the cost. They avoid the long waits at public clinics and the stigma of mental health care.

The lack of oversight is a concern. Without monitoring, patients risk toxicity or subtherapeutic dosing. Some private pharmacies offer a rudimentary service: they may check the patient's pulse and ask about side effects, but they do not draw blood. A few have partnered with private labs to offer lithium level testing for an additional fee, but uptake is low. The result is a fragmented system where the quality of care depends on the patient's ability to navigate it.

Wealthier patients also have access to private psychiatrists who can initiate and monitor lithium therapy. A consultation in a private clinic in Mumbai costs roughly $30–60, a sum that excludes most of the population. Those who can afford it receive close follow-up and dose adjustments. Those who cannot rely on valproate from the public clinic or self-medicate with lithium from the pharmacy down the street.

This two-tier system is not unique to bipolar disorder. Similar patterns exist for antipsychotics, antidepressants, and even antibiotics. An article on this site documents a parallel dynamic: the availability of a therapy does not guarantee its use, and clinicians often default to familiar alternatives. In mental health, the stakes are particularly high because the consequences of inadequate treatment can be devastating.

How a Simple Blood Test Becomes a Barrier to Best Practice

Lithium monitoring typically involves serum creatinine, eGFR, thyroid-stimulating hormone, and a lithium level—tests that cost roughly $10–20 in a private lab. For a patient earning $5 a day, that is a significant outlay, especially when repeated every six months. In public facilities, these tests may be offered free of charge, but reagent shortages and equipment breakdowns are common. In Malawi, a study found that public labs could not perform lithium levels for months at a time due to supply chain issues.

The barrier is not just financial. It is also logistical. A patient may need to travel to a district hospital to have blood drawn, then return a week later for results. Missed appointments are common, and patients may be lost to follow-up. Valproate, which requires only occasional liver function tests, imposes fewer demands. For a busy clinician managing a high caseload, the path of least resistance is to prescribe valproate and move on.

This is not to say that valproate is a poor drug. For many patients, it works well, and its side effect profile—sedation, weight gain, hair loss—is often more tolerable than lithium's tremor, thirst, and renal effects. But the choice should be based on individual patient characteristics, not on systemic constraints. When the system dictates the prescription, the doctor's clinical judgment is sidelined.

Some countries have tried to address this. In Ghana, a pilot program trained nurses at primary health centers to monitor lithium levels using point-of-care devices, reducing the need for lab visits. The devices, which cost roughly $500 each, can provide a lithium level from a fingerprick in under 10 minutes. Early results are promising, but scaling up requires investment and training. Similar programs in Kenya and Uganda have struggled to maintain supplies of test strips.

Practical Steps to Bridge the Lithium Access Gap Without Breaking Budgets

Decentralizing lithium monitoring to primary care is one strategy. Nurses and community health workers can be trained to follow simple algorithms for dose adjustment, as long as they have access to point-of-care testing. This has worked for HIV and tuberculosis, and there is no reason it cannot work for bipolar disorder. The key is to integrate mental health monitoring into existing chronic disease programs, reducing the need for specialist visits.

Pooled procurement of lithium and test strips could bring down costs. The Global Fund model for HIV drugs shows that negotiated bulk purchasing can reduce prices by 50% or more. The same approach could work for lithium, especially if countries coordinate through regional bodies like the African Union or ASEAN. The WHO could facilitate this by adding lithium monitoring supplies to its prequalification list.

Another approach is to train clinicians in the nuanced use of valproate, optimizing dosing and monitoring to achieve outcomes closer to lithium. While valproate may not match lithium's efficacy in all patients, better management of valproate could narrow the gap. This is not an either-or proposition: both drugs have a role, and the goal should be to match the right patient to the right drug, regardless of setting.

The pilot in Ghana offers a template. With modest investment, the program increased the proportion of patients on lithium from 8% to 22% over two years, without any serious adverse events. The cost per patient was roughly $15 per year for monitoring, a fraction of the potential savings from reduced hospitalizations. Scaling such programs requires political will and a shift in mindset: from seeing lithium as a burden to seeing it as an investment.

In addition to these strategies, a growing body of research supports the use of lithium in low-resource settings when properly managed. A 2024 study in BMC Psychiatry examined a cohort of 350 patients in rural Ethiopia who were started on lithium through a task-sharing program with community health workers. After one year, 72% of patients achieved stable mood, and only 2% experienced serious adverse events. The program used a simplified algorithm: patients received a fixed starting dose of 300 mg twice daily, with dose adjustments based on clinical response and a single lithium level drawn at three months. The study suggests that with basic training and limited lab access, lithium can be used safely even where resources are scarce.

Another promising development is the use of point-of-care lithium testing devices that cost under $200 per device and provide results in minutes. These devices are being piloted in India, Kenya, and Brazil. Early data from a pilot in Karnataka, India, showed that nurses could perform the test with 95% accuracy compared to standard lab methods. If these devices become widely available, they could remove the monitoring barrier entirely, allowing public clinics to prescribe lithium with confidence.

However, even with these innovations, the two-tier system will persist unless governments commit to funding mental health equitably. A 2023 report from the World Health Organization noted that low-income countries spend a median of less than $2 per capita on mental health, compared to over $50 in high-income countries. Until that gap narrows, the default to valproate will remain a pragmatic necessity for most public clinics.